The Georgetown University Memory Disorders Program is dedicated to providing state-of-the-art clinical services for individuals affected by Alzheimer's disease and related disorders and to conducting research aimed at improving treatment options for Alzheimer's disease.

MARK YOUR CALENDARS

Please join us for a screening of a new documentary, "The Sum Total of Our Memory: Facing Alzheimer's Together " on October 1st starting at 5:45PM. There will be a panel discussion following the screening and wine & hors d'oeuvres will be served. RSVP here: http://www.eventbrite.com/e/the-sum-total-of-our-memory-screening-oct-1-tickets-18348206981

Please join us for the October 24, 2015 Alzheimer's Association Memory Walk on the Mall. Our program is fielding a team called "The GUMC Memory Disorders Program."   You are welcome to join us on the National Mall, 15th and Constitution Ave., NW. Register on the website here. Check in begins at 8:30AM and the Walk starts at 10:00AM. To donate to our team click here. Hope to see you there.

WE ARE ON FACEBOOK

"Like" our facebook page to stay up to date on research findings and helpful information

JOIN OUR MAILING LIST!

Would you like to receive our Spring newsletter? Sign up here to receive our newsletter either in the mail or via email. We send out two newsletters a year to everyone on our mailing list and as well invitations to our yearly fall appreciation event.

Research Studies

Here are our research studies that are currently recruiting patients.

Title Sponsor
Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss (A4) ADCS/ Eli Lilly and Company

An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738 AM3) (EPOCH)

Merck

DOD-ADNI: A Study of Brain Aging in Vietnam War Veterans

ADCS

Efficacy and Safety of T-817MA in Patients With Mild to Moderate Alzheimer's Disease (NOBLE)

ADCS/Toyama Chemical Co.

Efficacy and Safety Trial of MK-8931 in Participants With Prodromal Alzheimer's Disease (MK-8931-019) (APECS)

Merck

A Phase IIa Multi-Center Study of 18F-FDG PET, Safety, and Tolerability of AZD0530 in Mild Alzheimer's Disease

ADCS and Yale University

Check out our Research section for more information on how to participate in our clinical trials.

Make a Donation

For information about how to make a tax-deductible contribution to the Memory Disorders Program, please click here.